FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068228017> ?p ?o ?g. }

• W2068228017 endingPage "988" @default.
• W2068228017 startingPage "981" @default.
• W2068228017 abstract "No AccessJournal of UrologyInvestigative Urology1 Sep 2012Mifepristone Inhibits GRβ Coupled Prostate Cancer Cell Proliferation Martin Ligr, Yirong Li, Susan K. Logan, Samir Taneja, Jonathan Melamed, Hebert Lepor, Michael J. Garabedian, and Peng Lee Martin LigrMartin Ligr Department of Pathology, New York University Cancer Institute, New York, New York Department of Medicine, New York University Cancer Institute, New York, New York More articles by this author , Yirong LiYirong Li Department of Pathology, New York University Cancer Institute, New York, New York More articles by this author , Susan K. LoganSusan K. Logan Department of Urology, New York University Cancer Institute, New York, New York Department of Pharmacology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author , Samir TanejaSamir Taneja Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York Financial interest and/or other relationship with Eigen, GTX, Janssen, Histoscanning and Steba Biotech. More articles by this author , Jonathan MelamedJonathan Melamed Department of Pathology, New York University Cancer Institute, New York, New York More articles by this author , Hebert LeporHebert Lepor Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author , Michael J. GarabedianMichael J. Garabedian Department of Urology, New York University Cancer Institute, New York, New York Department of Microbiology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author , and Peng LeePeng Lee Department of Pathology, New York University Cancer Institute, New York, New York Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York New York University School of Medicine and New York Harbor Healthcare System, New York, New York More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.04.102AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The GR gene produces GRα and GRβ isoforms by alternative splicing of a C-terminal exon. GRα binds glucocorticoids, modulates transcription in a glucocorticoid dependent manner and has a growth inhibitory role in prostate cells. Due to this role glucocorticoids are often used to treat androgen independent prostate cancer. In contrast, GRβ has intrinsic transcriptional activity and binds mifepristone (RU486) but not glucocorticoids to control gene expression. To our knowledge the role of GRβ in prostate cell proliferation is unknown. Materials and Methods: We determined GRβ levels in various prostate cancer cell lines by reverse transcriptase-polymerase chain reaction and Western blot. The effect of GRβ on the kinetics of prostate cancer cell growth was determined by cell counting and flow cytometry upon mifepristone and dexamethasone treatment. Cell proliferation was also examined after siRNA mediated knockdown and over expression of GRβ. Results: GRβ mRNA and protein were up-regulated in LNCaP cells that over expressed the androgen receptor co-factor ARA70β. Treatment of LNCaP-ARA70β with mifepristone or siRNA targeting GRβ inhibited proliferation compared to that of parental LNCaP cells. The immortal but nontumorigenic RC165 prostate cell line and the tumorigenic DU145 prostate cell line with endogenous GRβ also showed partial growth reduction upon GRβ depletion but to a lesser extent than LNCaP-ARA70β cells. The growth stimulatory effect of ARA70β on LNCaP cells was partly GRβ dependent, as was the proliferation of RC165 cells and to a lesser extent of DU145 cells. Conclusions: Results suggest that patients with a primary tumor that expresses GRβ and ARA70β may benefit from mifepristone. References 1 : The biology of hormone refractory prostate cancer: Why does it develop?. Urol Clin North Am1999; 26: 263. Google Scholar 2 : Glucocorticoid receptor signaling and prostate cancer. Cancer Lett2011; 302: 1. Google Scholar 3 : Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology2002; 60: 553. Google Scholar 4 : Androgen and glucocorticoid receptor heterodimer formation: A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem1997; 272: 14087. Google Scholar 5 : Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst2001; 93: 1739. Google Scholar 6 : Glucocorticoid up-regulates transforming growth factor-beta (TGFβ) type II receptor and enhances TGFβ signaling in human prostate cancer PC-3 cells. Endocrinology2006; 147: 5259. Google Scholar 7 : Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res2006; 12: 3003. Google Scholar 8 : The development of androgen-independent prostate cancer. Nat Rev Cancer2001; 1: 34. Google Scholar 9 : Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med2000; 6: 703. Google Scholar 10 : Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol2009; 300: 7. Google Scholar 11 : Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem2011; 286: 3177. Google Scholar 12 : The human glucocorticoid receptor beta isoform: Expression, biochemical properties, and putative function. J Biol Chem1996; 271: 9550. Google Scholar 13 : Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest1995; 95: 2435. Google Scholar 14 : Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol2007; 27: 2266. Google Scholar 15 : Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70β. Am J Pathol2008; 172: 225. Google Scholar 16 : Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol1999; 69: 307. Google Scholar 17 : Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol1999; 69: 3. Google Scholar 18 : Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1a with multiple steroid receptors and identification of an internally deleted ELE1b isoform. Mol Endocrinol1999; 13: 117. Google Scholar 19 : Tumor suppressor function of androgen receptor coactivator ARA70α in prostate cancer. Am J Pathol2010; 176: 1891. Google Scholar 20 : Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology1999; 140: 5054. Google Scholar 21 : Androgen receptor coactivator ARA70α and ARA70β isoform-specific antibodies: new tools for studies of expression and immunohistochemical localization. Appl Immunohistochem Mol Morphol2008; 16: 7. Google Scholar 22 : Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab1999; 84: 4283. Google Scholar 23 : Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res2006; 312: 831. Google Scholar 24 : Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer. Urol Int2008; 81: 228. Google Scholar 25 : Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. J Steroid Biochem Mol Biol2009; 116: 29. Google Scholar 26 : Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology1998; 52: 252. Google Scholar 27 : Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer2000; 89: 2570. Google Scholar 28 : Glucocorticoid receptor-beta and receptor-gamma exert dominant negative effect on gene repression but not on gene induction. Endocrinology2010; 151: 3204. Google Scholar 29 : Low glucocorticoid receptor alpha/beta ratio in T-cell lymphoblastic leukemia. Horm Metab Res2000; 32: 401. Google Scholar 30 : A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int2008; 101: 1084. Google Scholar © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2018) Re: PLCε Knockdown Inhibits Prostate Cancer Cell Proliferation via Suppression of Notch Signalling and Nuclear Translocation of the Androgen ReceptorJournal of Urology, VOL. 195, NO. 2, (524-525), Online publication date: 1-Feb-2016. Volume 188Issue 3September 2012Page: 981-988 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Keywordsmifepristonegene expressionprostateprostatic neoplasmsreceptorsglucocorticoidMetricsAuthor Information Martin Ligr Department of Pathology, New York University Cancer Institute, New York, New York Department of Medicine, New York University Cancer Institute, New York, New York More articles by this author Yirong Li Department of Pathology, New York University Cancer Institute, New York, New York More articles by this author Susan K. Logan Department of Urology, New York University Cancer Institute, New York, New York Department of Pharmacology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author Samir Taneja Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York Financial interest and/or other relationship with Eigen, GTX, Janssen, Histoscanning and Steba Biotech. More articles by this author Jonathan Melamed Department of Pathology, New York University Cancer Institute, New York, New York More articles by this author Hebert Lepor Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author Michael J. Garabedian Department of Urology, New York University Cancer Institute, New York, New York Department of Microbiology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York More articles by this author Peng Lee Department of Pathology, New York University Cancer Institute, New York, New York Department of Urology, New York University Cancer Institute, New York, New York New York University Cancer Institute, New York University Cancer Institute, New York, New York New York University School of Medicine and New York Harbor Healthcare System, New York, New York More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2068228017 created "2016-06-24" @default.
• W2068228017 creator A5001126593 @default.
• W2068228017 creator A5009486201 @default.
• W2068228017 creator A5011447518 @default.
• W2068228017 creator A5015295981 @default.
• W2068228017 creator A5038293438 @default.
• W2068228017 creator A5043064773 @default.
• W2068228017 creator A5060305478 @default.
• W2068228017 creator A5062397416 @default.
• W2068228017 date "2012-09-01" @default.
• W2068228017 modified "2023-10-18" @default.
• W2068228017 title "Mifepristone Inhibits GRβ Coupled Prostate Cancer Cell Proliferation" @default.
• W2068228017 cites W1517035469 @default.
• W2068228017 cites W1967795360 @default.
• W2068228017 cites W1974791065 @default.
• W2068228017 cites W1976158428 @default.
• W2068228017 cites W1978960998 @default.
• W2068228017 cites W1997282581 @default.
• W2068228017 cites W2005658600 @default.
• W2068228017 cites W2006734017 @default.
• W2068228017 cites W2018472946 @default.
• W2068228017 cites W2025347885 @default.
• W2068228017 cites W2036054914 @default.
• W2068228017 cites W2044170670 @default.
• W2068228017 cites W2058081875 @default.
• W2068228017 cites W2059633037 @default.
• W2068228017 cites W2074607560 @default.
• W2068228017 cites W2078814775 @default.
• W2068228017 cites W2081684816 @default.
• W2068228017 cites W2089333807 @default.
• W2068228017 cites W2091569641 @default.
• W2068228017 cites W2100858556 @default.
• W2068228017 cites W2101778252 @default.
• W2068228017 cites W2134741264 @default.
• W2068228017 cites W2143578597 @default.
• W2068228017 cites W2168011358 @default.
• W2068228017 cites W2169702768 @default.
• W2068228017 cites W2171755262 @default.
• W2068228017 cites W4229892124 @default.
• W2068228017 cites W4249563438 @default.
• W2068228017 cites W4253096778 @default.
• W2068228017 cites W2044802727 @default.
• W2068228017 doi "https://doi.org/10.1016/j.juro.2012.04.102" @default.
• W2068228017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3646901" @default.
• W2068228017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23201377" @default.
• W2068228017 hasPublicationYear "2012" @default.
• W2068228017 type Work @default.
• W2068228017 sameAs 2068228017 @default.
• W2068228017 citedByCount "25" @default.
• W2068228017 countsByYear W20682280172013 @default.
• W2068228017 countsByYear W20682280172014 @default.
• W2068228017 countsByYear W20682280172015 @default.
• W2068228017 countsByYear W20682280172016 @default.
• W2068228017 countsByYear W20682280172017 @default.
• W2068228017 countsByYear W20682280172018 @default.
• W2068228017 countsByYear W20682280172020 @default.
• W2068228017 countsByYear W20682280172021 @default.
• W2068228017 countsByYear W20682280172022 @default.
• W2068228017 crossrefType "journal-article" @default.
• W2068228017 hasAuthorship W2068228017A5001126593 @default.
• W2068228017 hasAuthorship W2068228017A5009486201 @default.
• W2068228017 hasAuthorship W2068228017A5011447518 @default.
• W2068228017 hasAuthorship W2068228017A5015295981 @default.
• W2068228017 hasAuthorship W2068228017A5038293438 @default.
• W2068228017 hasAuthorship W2068228017A5043064773 @default.
• W2068228017 hasAuthorship W2068228017A5060305478 @default.
• W2068228017 hasAuthorship W2068228017A5062397416 @default.
• W2068228017 hasBestOaLocation W20682280172 @default.
• W2068228017 hasConcept C121608353 @default.
• W2068228017 hasConcept C126322002 @default.
• W2068228017 hasConcept C126894567 @default.
• W2068228017 hasConcept C143998085 @default.
• W2068228017 hasConcept C2776235491 @default.
• W2068228017 hasConcept C2778826759 @default.
• W2068228017 hasConcept C2779234561 @default.
• W2068228017 hasConcept C2780192828 @default.
• W2068228017 hasConcept C29456083 @default.
• W2068228017 hasConcept C502942594 @default.
• W2068228017 hasConcept C54355233 @default.
• W2068228017 hasConcept C62112901 @default.
• W2068228017 hasConcept C71924100 @default.
• W2068228017 hasConcept C86803240 @default.
• W2068228017 hasConceptScore W2068228017C121608353 @default.
• W2068228017 hasConceptScore W2068228017C126322002 @default.
• W2068228017 hasConceptScore W2068228017C126894567 @default.
• W2068228017 hasConceptScore W2068228017C143998085 @default.
• W2068228017 hasConceptScore W2068228017C2776235491 @default.
• W2068228017 hasConceptScore W2068228017C2778826759 @default.
• W2068228017 hasConceptScore W2068228017C2779234561 @default.
• W2068228017 hasConceptScore W2068228017C2780192828 @default.
• W2068228017 hasConceptScore W2068228017C29456083 @default.
• W2068228017 hasConceptScore W2068228017C502942594 @default.
• W2068228017 hasConceptScore W2068228017C54355233 @default.
• W2068228017 hasConceptScore W2068228017C62112901 @default.
• W2068228017 hasConceptScore W2068228017C71924100 @default.
• W2068228017 hasConceptScore W2068228017C86803240 @default.
• W2068228017 hasIssue "3" @default.

• next